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?????? ????? ???????? ????? ??? ?? ???????????? ?????????????????? ???????? causing   irreversible  
cognitive  decline  in  the  elderly.  There  is  no  disease-­‐modifying  therapy  for  this  condition  and  
the   mechanisms   underpinning   neuronal   dysfunction   and   neurodegeneration   are   unclear.  
Compromised   cytoskeletal   integrity   within   neurons   is   reported   in   AD.   This   is   believed   to  
result   from   loss-­‐of-­‐function   of   the   microtubule-­‐associated   protein   tau,   which   becomes  
hyper-­‐phosphorylated  and  deposits  into  neurofibrillary  tangles  in  AD.  We  have  developed  a  
Drosophila   model   of   tauopathy   in   which   abnormal   human   tau   mediates   neuronal  
dysfunction   characterized   by   microtubule   destabilization,   axonal   transport   disruption,  
synaptic  defects  and  behavioural  impairments.  Here  we  show  that  a  microtubule-­‐stabilising  
drug,   NAP,   prevents   as  well   as   reverses   these   phenotypes   even   after   they   have   become  
established.  Moreover  it  does  not  alter  abnormal  tau  levels  indicating  that  it  by-­‐passes  toxic  
tau   altogether.   Thus  microtubule   stabilization   is   a   disease-­‐modifying   therapeutic   strategy  
protecting   against   tau-­‐mediated   neuronal   dysfunction   which   holds   great   promise   for  
tauopathies  like  AD.  
  













Although   ?????? ????? ???????? ?AD)   was   first   described   over   100   years   ago,   the  
neurodegenerative   mechanisms   underpinning   this   disease   remain   unclear.   Thus   disease-­‐
modifying   therapies   still   elude  us   and   treatment   is   restricted   to  provision  of   symptomatic  
relief1.  One  avenue  of  research  investigates  how  hyper-­‐phosphorylated  tau,  a  microtubule-­‐
associated   protein   forming   the   tangle   pathology   in   AD,   causes   neuronal   dysfunction   and  
degeneration.  Hyper-­‐phosphorylated  tau  cannot  effectively  bind  and  stabilise  microtubules.  
It   is   hypothesised   that   this   compromises   cytoskeletal   integrity  within   affected   neurons   in  
AD2-­‐4,   disrupting   axonal   transport   and   synaptic   function5,   6   and   manifesting   in   clinical  
symptoms7.   Compromised   and   reduced   numbers   of   microtubules   are   reported   in   post-­‐
mortem  AD  brains8.  Furthermore,  a  direct  correlation  between  hyper-­‐phosphorylated  tau-­‐
mediated   axonal   transport   disruption   and   behavioural   impairment   is   demonstrated   in  
Drosophila  (htau0N3R)  and  rodent  (tau-­‐T44  tg  mice)  models  of  AD6,  9.  Supporting  this,  tangle  
pathology   closely   correlates   with   cognitive   decline   in   AD   patients10.   Hence,   tau-­‐based  
therapies  are  being  considered   for  AD11,  12.  Current   strategies   include  drugs   to   reduce   tau  
phosphorylation   and   aggregation.   Recently,   the   use   of   microtubule-­‐stabilising   drugs   to  
compensate   for   tau   loss-­‐of-­‐function   has   been   explored13.   Paclitaxel,   a   microtubule-­‐
stabilising   drug,   reduces   axonopathy   and   improves   behaviour   in   a   rodent   model   of  
tauopathy14.   Though   this   supports   the   idea   of   by-­‐passing   pathogenic   tau   by   directly  
stabilising  microtubules,  the  high  toxicity  and  poor  blood-­‐brain-­‐barrier  (BBB)  permeability  of  
such  drugs  make  them  unsuitable  for  treating  patients.  This  prompted  the  development  of  a  
new   generation   of   microtubule-­‐stabilising   agents   exhibiting   low   toxicity   and   high   BBB  
permeability15.  




   The   small   octapeptide   NAPVSIPQ   (NAP),   derived   from   activity-­‐dependent  
neuroprotective  protein15,  interacts  with  and  stabilises  neuron-­‐?????????????-­‐tubulin  in-­‐vitro16.  
Importantly,  NAP  penetrates  the  BBB  and  is  non-­‐toxic17,  18.  The  neuroprotective  activities  of  
NAP  are  documented  in  many  in-­‐vivo  and  in-­‐vitro  models19.  Studies  in  rodent  models  of  AD,  
suggest  that  ??????????????????????????is  mediated  by  its  ability  to  stabilise  the  microtubule  
cytoskeleton20-­‐22.    However,  this  is  yet  to  be  demonstrated  in-­‐vivo.    
Here  we   show   that  NAP  by-­‐passes   abnormal   tau   and   compensates   for   tau   loss-­‐of-­‐
function  thus  protecting  against  neuronal  dysfunction   in  a  Drosophila  model  of  tauopathy.  
This   model   is   ideally   suited   for   this   investigation   because   the   phenotypes   arise   as   a  




















Stocks  and  drug  treatment:  Expression  of  htau0N3R  (Bloomington  Stock  Centre  ?  USA;  stock  
no.   181),   htau1N4R   (provided  by  Dr.   E.   Skoulakis;   Alexander   Fleming   Institute,  Greece)   and  
amyloid  beta-­‐42  (A?42):A?42;htau1N4R  (provided  by  Dr.  D.  Crowther;  University  of  Cambridge,  
UK)  was  directed  to  Drosophila  melanogaster  motor  neurons  using  either  the  motor  neuron  
specific   drivers      D42-­‐Gal4,   or   the   D42-­‐Gal4   driver   recombined   with   GFP-­‐tagged  
neuropeptide-­‐Y   (D42-­‐GAL4.UAS-­‐NPY:GFP)6   (UAS-­‐NPY:GFP   provided   by   Dr.   I.   Robinson,  
University  of  Cambridge,  UK).  Pan-­‐neural  expression  was  achieved  with  the  Elav-­‐Gal4  driver  
(Bloomington  Stock  Centre  ?  USA;  stock  no.  458).  NAP  (Peptide  Protein  Research,  UK)  was  
delivered  to  basic  fly  food  at  concentrations  of  50ng/ml,  500ng/ml,  2.5µg/ml  or  25µg/ml.    
  
Larval   locomotion   and   electron   microscopy   analysis   were   conducted   as   previously  
described23,4.    
  
In-­‐vivo  axonal  transport  analysis.  Treatment  groups  were  subjected  to  timed  lays  on  apple  
juice   agar   plates.   F1   eggs   were   transferred   to   basic   or   NAP   food.   Htau0N3R   larvae   were  
assessed   at   L3   wandering   stage   (day   5)   at   23°C.   Htau1N4R   and   A?42;htau1N4R   larvae   were  
reared  at   29°C.   For   the  NAP   rescue  experiment,   early   L3   larvae  were   removed   from   food  
plates  at  day  4  and  either  subjected  to  axonal  transport  analysis  or  moved  onto  a  basic  food  
plate  or  a  NAP  food  plate  for  24h.  Axonal  transport  was  analysed  as  previously  described6,  24.    
  
Immunohistochemistry.  Dissected  L3  larvae  were  immuno-­‐stained  as  previously  described5.  
Body  walls  were   incubated   in   goat   anti-­‐HRP   conjugated   to   FITC   (1:1000;   ICN/Cappel)   and  
mouse  anti-­‐tubulin   (1:500;   E7-­‐Developmental  Hybridoma  Bank)   antibodies   and  with  Alexa  




Fluor®   594   donkey   anti-­‐mouse   (1:200;   Invitrogen)   secondary   antibody.   Muscle   4   from  
abdominal  segments  A3-­‐A7  was  imaged5.  
  
Microtubule-­‐binding   assay.   3   heads   of   1-­‐3d-­‐old   flies,   or   10   larval   (L3)   ventral   cords  were  
pooled  and  homogenised  in  30µl  and  40µl  respectively  of  microtubule-­‐binding  assay  buffer  
as  previously  described4.    
  
Immunopreciptiation   assay.   10   heads   of   1-­‐3d-­‐old   flies   were   homogenised   in   500   µl   of  
microtubule-­‐binding  assay  buffer  and  interactions  between  htau0N3R  and  dtau  were  assessed  
as  described  previously4.    
  
Western   blotting.   Adult   heads   or   dissected   L3   larval   ventral   cords   were   homogenised,  
resolved  by  SDS-­‐PAGE  and  probed  as  previously  described6,26.  Blots  were  probed  with  anti-­‐
human  tau  (1:15,000,  Dako),  anti-­‐dtau  (1:500,  Prof.  St.  Johnston,  University  of  Cambridge),  
anti-­‐phospho-­‐tau:  PHF-­‐1  (1:2000  Dr.  Peter  Davies,  Albert  Einstein  College  of  Medicine,  NY),  
AT180  (1:100,  Biosciences),  AT8  (1:800,  Bioscience),  tau-­‐1  (1:2000,  Millipore),  pS262  (1:1000,  
Invitrogen),  anti-­‐tubulin  (1:200)  and  anti-­‐kinesin  (1:5000,  Cytoskeleton).  Signal  was  detected  
using  fluorescently-­‐conjugated  secondary  antibodies.  
  
Statistics.  Statistical  analysis  was  carried  out  using  Prism  5.0  (GraphPad).    T-­‐test  or  one-­‐way  
ANOVA,  with  ????????????? ??????????????????  post-­‐hoc  analysis.    
  
Results  




NAP   prevents   htau0N3R-­‐mediated   disruption   of   locomotor   behaviour.   Expression   of   the  
highly  phosphorylated  0N3R  human  tau   isoform   (htau0N3R)  in  motor  neurons  of  Drosophila  
manifests  in  a  number  of  distinct  phenotypes  including  crawling  defects  in  larvae6.  We  first  
tested   whether   this   phenotype   could   be   prevented   by   NAP.   Untreated   htau0N3R   larvae  
exhibited   a   restricted   and   non-­‐continuous   crawling   behaviour   (Fig.   1B;   Suppl.   Video   1)  
compared   with   controls   (Fig.   1A;   Suppl.   Video   2).   This   defective   crawling   behaviour  
improved   significantly   following   NAP   treatment   leading   to   smoother,   more   directed  
movement  over  a  greater  distance   like  controls  (Fig.  1C;  Suppl.  Video  3).  Using  the  image-­‐
tracking   software   Ethovision,   crawling   parameters   were   quantified   including   body   wall  
contractions,   velocity   and   meander   (turning   rate   per   distance   travelled).   ????????? ????
significantly  improved  body  wall  contractions  and  velocity  compared  to  un-­‐treated  htau0N3R  
larvae  (Fig.  1D,E).    Meander  was  also  improved,  but  did  not  reach  significance  (P=0.06)  (Fig.  
1F).    Crawling  behaviour  of  controls  treated  with  NAP  was  no  different  to  untreated  controls  
(Suppl.  Fig  1).    
  
NAP   stabilises  microtubules   and   improves   axonal   transport   and  NMJ  morphology.  Since  
disruption   of   the   microtubule   cytoskeleton   causes   behavioural   defects   in   this   model,   we  
investigated  whether  microtubule   stabilisation  was   the  mechanism  by  which  NAP   rescued  
the   locomotor   phenotype   of   htau0N3R   larvae.   The   ultrastructural   organisation   of   the  
microtubule   cytoskeleton   was   examined   in   transverse   sections   of   peripheral   nerves   by  
transmission   electron   microscopy   (EM).   Controls   displayed   characteristic,   25nm   circular  
transverse   microtubule   profiles   (black   arrows   Fig.   2A-­‐C).   In   contrast,   htau0N3R   larvae   had  
noticeably   fewer   such   microtubule   profiles   and   displayed   many   disorganised   and   mis-­‐
aligned  microtubules   (black  arrowheads  Fig.  2D-­‐F).  A  number  of  axons  relatively  devoid  of  




microtubules  were  also  evident   in  htau0N3R   larvae   (asterisks  Fig.   2F).  NAP   re-­‐stabilised   the  
disrupted   and   disorganised  microtubules   as   evidenced   by   the   appearance   of  more   intact  
transverse   microtubule   profiles   in   treated   compared   to   untreated   htau0N3R   larvae   (black  
arrows   Fig.   2G-­‐I).   Quantification   of   the   number   of   intact   microtubule   profiles   per   axon  
confirmed  that  there  were  significantly  fewer  microtubule  profiles  in  htau0N3R  axons  (5.32  ±  
0.28)  compared  to  controls  (8.10  ±  0.20).  NAP  increased  this  number  back  to  control  levels  
(8.07  ±  0.30)  (Fig.  2J).  The  range  of  intact  microtubules  per  individual  axon  in  each  condition  
is   illustrated   in   Fig.   2K.   Almost   half   the   axons   from   controls   contained   large   numbers   of  
microtubules   (>5),   with   very   few   axons   containing   no   microtubules   (1%).   However,   the  
majority   (~65%)   of   htau0N3R   axons   contained   either   none   (30%)   or   very   few   (<5)  
microtubules  (35%).  In  contrast,  the  peripheral  nerves  of  NAP-­‐treated  htau0N3R  larvae  had  a  
similar   microtubule   profile   to   controls.   There   was   an   increase   in   the   number   of   axons  
containing   large   numbers   (>5)   of   intact   transverse   microtubules   (58%)   compared   to  
untreated  htau0N3R  (35%),  and  a  reduction  in  the  number  of  axons  with  no  microtubules  (7%)  
(Fig.   2K).      NAP-­‐treatment   did   not   change   the   number   of  microtubule   profiles   in   controls  
(untreated   controls   had   9.22  ±   0.42   intact  MT  profiles  whereas  NAP-­‐treated   controls   had  
9.98  ±  0.45  intact  MT  profiles;  Suppl.  Fig  2).      
We   next   investigated   whether   the   restoration   of   microtubule   integrity   in   NAP-­‐
treated   htau0N3R   larvae   improves   axonal   transport   since  we   know   that   axonal   transport   is  
disrupted   in   this   model   as   a   consequence   of   microtubule   breakdown6.   Expression   of  
vesicular   neuropeptide-­‐Y-­‐GFP   (vGFP)   in   motor   neurons   of   larvae   allows   this   htau0N3R-­‐
mediated   phenotype   to   be   visualised   in-­‐vivo,   in   real   time,   in   living   intact   larvae.   A  
homogeneous   distribution   of   vGFP   indicating   efficient   axonal   transport   was   evident   in  
motor   neurons   of   NAP-­‐treated   and   untreated   controls   (Fig.   3A.i,   B.i).   As   expected,   in  




htau0N3R  larvae  the  distribution  of  vGFP  was  dramatically  different,  with  the  appearance  of  
large  vGFP  accumulates  within  axons,  illustrating  profound  axonal  transport  disruptions  (Fig.  
3C.i).  However,  in  NAP-­‐treated  htau0N3R  larvae  axonal  transport  appeared  normal,  with  very  
few   vGFP   accumulates   (Fig.   3D.i).   Quantification   of   the   total   area   occupied   by   vGFP  
accumulates  confirmed  this  result  (Fig.  3E).    A  ten-­‐fold  higher  dose  of  NAP  (25?g/ml)  did  not  
lead   to  any   further   improvement   (Fig   3E).  NAP  also   significantly   reduced  axonal   transport  
defects   in  animals  expressing   comparable   levels  of  another   tau   isoform   (htau1N4R  alone  or  
htau1N4R  and  A?42  (A?42;htau1N4R),  illustrating  that  NAP  can  rescue  defects  induced  by  both  3  
and  4  repeat  tau  isoforms  (Fig  3F  and  Suppl.  Fig  3).      
  Synaptic   function   and   neuromuscular   junction   (NMJ)   morphology   are   also  
compromised  in  our  model5.  To  ascertain  whether  the  protective  effect  of  NAP  extends  to  
the   synapse,   the   NMJ   on   muscle   4   was   visualised   using   an   antibody   against   a   neuronal  
surface  antigen  (anti-­‐HRP).  Anti-­‐tubulin  antibody  was  also  used  to  visualise  the  microtubule  
cytoskeleton  within  the  NMJ  terminals.  The  NMJ  morphology  in  controls  was  characterised  
by  a  bead-­‐like  distribution  of  pre-­‐synaptic  boutons   (Fig.   3A.ii-­‐iv).  The   tubulin  cytoskeleton  
extended   into   the   distal   ends   of   the   NMJ   (Fig.   3A.iii).   Neither   the   morphology   nor   the  
tubulin  cytoskeleton  of  these  controls  was  altered  by  NAP  (Fig.  3B.ii-­‐iv).  In  contrast,  htau0N3R  
larvae   NMJs   exhibited   profound   morphological   aberrations,   including   thinning   of   inter-­‐
bouton  axon   segments  and   appeara??????? ? ????? ????llite  boutons   (arrowheads  Fig.   3C.ii).  
The  cytoskeleton  was  also  disrupted,  with  a  complete  absence  of  tubulin  immuno-­‐reactivity  
in   the   most   distal   regions   (asterisk   Fig.   3C.iii).   NMJs   of   NAP-­‐treated   htau0N3R   larvae   also  
exhibited  morphological  aberrations  similar  to  those  of  untreated  htau0N3R  larvae,  but  with  a  
???????? ??????? ??? ? ????? ?????????? ???????? ?arrowheads   Fig.   3D.ii).      However,   the   tubulin  
cytoskeleton  in  these  animals  extended  into  the  most  distal  ends  of  the  NMJ  similar  to  that  




of   the   controls   (asterisks  Fig.   3D.iii).   The   area   encompassed  by   this  NMJ  was   significantly  
smaller   in  htau0N3R   larvae  compared  to  controls.  NAP  treatment  significantly   increased  this  
(Fig.  3G).    
  
Tau  phosphorylation   is   not   altered   by  NAP.  Hyper-­‐phosphorylation  of  htau   in  our  model  
reduces   its   (and   the  endogenous  Drosophila   tau   (dtau)??)  microtubule-­‐binding   ability   thus  
compromising  cytoskeletal  integrity4.  We  therefore  asked  whether  NAP  was  preventing  the  
emergence   of   the   htau0N3R-­‐mediated   phenotypes   by   reducing   tau   phosphorylation.   We  
examined  a  number  of  phospho-­‐tau  epitopes  associated  with  AD   in  both  NAP-­‐treated  and  
untreated  htau0N3R   larvae  and  adults.  NAP  did  not  alter   tau  phosphorylation  at  any  of   the  
sites  examined  (Fig.  4A-­‐D  and  Suppl.  Fig  4A-­‐E).  Though  there  was  a  trend  for  reduced  tau  
phosphorylation  at   thr231/235   (AT180)   following  NAP   treatment,   this  was  not   statistically  
significant  (P=0.3409)  (Fig.  4B).  Since  phospho-­‐tau  levels  were  unaltered,  we  next  explored  
the  possibility  that  NAP  was  protecting  the  htau0N3R   larvae  by   increasing  endogenous  dtau  
and/or  by  reducing  toxic  htau.  Neither  the  total  htau  or  dtau  levels  were  altered  by  NAP  in  
both  larvae  and  adults,  suggesting  that  NAP  does  not  block  or  enhance  degradation  of  these  
proteins   (Fig.   4E,F;   Suppl.   Fig.   4F,G).   Interestingly,   though   dtau   levels   were   unaltered   by  
NAP,   the   percentage   of   dtau   bound   to   MTs   increased   following   NAP   treatment   in   both  
htau0N3R-­‐expressing   larvae   and   adults   (Fig.   4G,H).   However,   htau   binding   to  MTs  was   not  
similarly   increased   (Fig.   4I,J).   This   sub-­‐cellular   redistribution   of   dtau   to   the  MTs   was   not  
attributable  to  a  reduction  of  pathological  htau0N3R/dtau  interaction  that  we  have  previously  
reported4  (Fig.  4K).  
  




NAP  not  only  prevents  the  emergence  of  tau  phenotype,  it  also  rescues  it  once  established.    
The  results   thus   far   show  that  NAP  prevents  the  emergence  of  hyper-­‐phosphorylated  tau-­‐
mediated  neuronal  and  behavioural  phenotypes.  To  investigate  whether  NAP  can  alter  tau  
phenotypes   if   administered   after   they   are   already   established,   we   devised   ?? ????????
??????????? In   this   protocol,   htau0N3R   larvae   were   reared   on   normal   food   for   4d   and   then  
transferred  to  food  containing  NAP   for  1d.  Axonal   transport  was  assessed  at  day  4  before  
NAP  treatment  was  begun  and  then  again  at  day  5,  after  only  1d  of  NAP  treatment.  Axonal  
transport  was  disrupted  in  untreated  htau0N3R   larvae  even  at  day  4  (light  grey  bar  Fig.  5A).  
However  NAP  treatment  for  1d  significantly  reduced  this  axonal  transport  disruption  (white  
bar  Fig.   5A).   Importantly,   this   rescue   of   axonal   transport  deficit   following   only  1d  of  NAP  
treatment   was   the   same   as   if   it   were   given   continuously   for   5d   (striped   bar   Fig.   5A).  
Furthermore,  the  rescue  persisted  even  if  htau0N3R  larvae  reared  on  NAP  for  4d  were  taken  
off  the  drug  and  reared  on  normal  food  for  a  further  1d  (dark  grey  bar  Fig.  5A).  Overall  the  
deficits  observed  at  day  5  in  all  htau0N3R  larvae  reared  on  these  variations  of  NAP  treatment  
was  significantly  less  than  that  observed  in  untreated  htau0N3R  larvae  reared  on  normal  food  
for  5d.  (black  bar  Fig.  5A).   Interestingly,   if  NAP  treatment  was  not  begun  at  any  point,  the  
axonal  transport  disruption  became  progressively  worse  as  the  animals  aged  from  day  4  to  
day  5  (1st  grey  bar  vs  black  bar  in  Fig.  5A).    
To  confirm  the  low  toxicity  of  NAP16,22,27-­‐29,  we  assessed  pupariation/ecclosion  rates  
of   control   and   htau0N3R   larvae   with   and   without   NAP   treatment.   NAP   did   not   affect  









We  demonstrate  that  compensating  for  tau  loss-­‐of-­‐function  by  stabilising  microtubules  is  a  
disease-­‐modifying   therapeutic   strategy   that   should   be   considered   for   the   treatment   of  
tauopathies.   We   show   that   treatment   with   the   microtubule-­‐stabilising   peptide   NAP  
significantly  improves  all  phenotypes  caused  by  expression  of  highly  phosphorylated  tau  in-­‐
vivo.   This   includes   reinstatement   of   cytoskeletal   integrity,   prevention   of   axonal   transport  
and   synaptic   dysfunction   and   improvement   of   behavioural   defects.   Intriguingly,   though  
hyper-­‐phosphorylated  tau  is  considered  to  be  the  toxic  species  in  tauopathies,  NAP  rescued  
all   phospho-­‐tau   phenotypes   without   altering   phosphorylation   at   key   disease-­‐associated  
epitopes.   Furthermore,   NAP   treatment   is   sufficient   to   rescue   neuronal   dysfunction   even  
after  it  has  already  become  established.  Thus  NAP  prevents,  but  more  importantly,  rescues  
phospho-­‐tau  mediated  neuronal  dysfunction  in-­‐vivo.      
  
NAP  stabilises  microtubules  
Microtubule   integrity   is   critical   for   intracellular   transport   of   materials   and   cytoskeletal  
dysfunction   contributes   to   degeneration   in   many   neurodegenerative   conditions.   Our  
previous  findings   illustrate   that,  microtubule  destabilisation  caused  by  tau-­‐loss-­‐of-­‐function  
is  a  key  mechanism  by  which  highly-­‐phosphorylated  tau  mediates  neuronal  dysfunction4,  6.  
In   other   models   too,   tau-­‐loss-­‐of   function   and   subsequent   trafficking   impairments   cause  
neurodegeneration25.   The   data   presented   here   further   underlines   this   and   demonstrates  
that  microtubule  stabilisation  can  effectively  protect  against  this.    
Taxol-­‐based   microtubule-­‐stabilising   drugs   are   considered   for   treating   AD11,  13,  26,  27  
but  their  wide-­‐spread  toxicity  and  poor  BBB  penetrability  precludes  their  use.  To  overcome  
this,  a  newer  generation  of  drugs  like  small  peptides  (NAP)  and  small  molecules  (Epothilones  




e.g.  EpoD)  have  been  formulated28-­‐30.  Both  NAP  and  EpoD  interact  with  MTs  in-­‐vitro,  reduce  
axonopathy  and  improve  behaviour  with  minimal  toxicity   in  rodent  models  of  tauopathy29,  
31.  In  agreement  with  these  studies  we  also  report  an  improvement  in  behavioural  deficits  of  
htau0N3R-­‐expressing  larvae  following  treatment  with  NAP.  However,  we  further  extend  these  
findings  and  demonstrate  for  the  first  time  that  re-­‐instatement  of  the  structure  and  function  
of   microtubules   is   the   mechanism   by   which   NAP   confers   neuroprotection   in-­‐vivo.    
Furthermore,  our  study  pioneers  evaluations  of  live  axonal  transport  directly  visualised  in  a  
living   intact   animal   treated   with   NAP,   or   indeed   any   other   microtubule-­‐stabilising   agent.  
Corroborating   studies   in   rodents   using   Mn++   enhanced   magnetic   resonance   imaging   are  
underway32.    
We  also  observed  that  NAP  restored  the  tubulin  cytoskeleton  within  NMJs,  and  the  
resultant   impact   on   synaptic   function   will   have   contributed   to   the   behavioural  
improvements   seen   following   NAP   treatment.   Furthermore,   NAP   has   been   shown   to  
increase   expression   of   the   synaptic   protein   synaptophysin   in   neuronal   cultures33   and   in-­‐
vivo34   which   is   associated   with   neuroprotection35.      However   the   NMJs   of   NAP   treated  
htau0N3R-­‐expressing   animals   had  a   greater  number  of   ??????? ?????????? ?????????which  may  
reflect  compensatory  sprouting  to  maintain  neuronal  function.  Indeed  NAP  has  been  shown  
to  induce  neurite  outgrowth  in-­‐vitro16,  and  this  would  support  our  observations.  
The   molecular   mechanism   by   which   NAP   stabilises   MTs   is   not   known.   We  
hypothesize  that  NAP  directly  associates  with  MTs  and  modulates  their  dynamics.  In  support  
for  this,  NAP  directly  co-­‐localises  with  tubulin16,  36  and  alters  MT  dynamics  in  cell  culture37.  
Our   data   also   suggests   that   disorientated/misaligned   MTs   (such   as   those   present   in   the  
htau-­‐expressing   larvae4)   are   ?????? ????? likely   substrate   which   is   why   it   does   not   alter  
cytoskeletal   integrity   (and  therefore  neuronal   function  or  behaviour)   in  controls.  This   is   in  




complete   agreement   with   recent   studies   showing   a   more   robust   effect   on   MT  
polymerization  in  the  compromised  state37,  38.    
  
NAP  by-­‐passes  hyper-­‐phoshorylated  tau  
Clinical   research   in   AD   has   largely   focused   on   anti-­‐amyloid   therapies,   but   the   growing  
consensus  now  is  that  truly  effective  disease-­‐modifying  therapies  will  need  to  target  tau  as  
well.   Thus   tau-­‐based   therapeutic   targets   are   eagerly   anticipated.   Agents   that   reduce   tau  
phosphorylation  and  aggregation  are  currently  being  tested  in  clinical  trials1,  39.  Interestingly,  
we   find   that  microtubule   stabilisation   rescues   neuronal   dysfunction   by   by-­‐passing   hyper-­‐
phosphorylated  tau  altogether  and  directly  compensating  for  its  detrimental  effects.  Similar  
results   were   reported   in   a   rodent  model   of   tauopathy   in  which   EpoD   improves   cognitive  
performance  without  altering  tau  phosphorylation  in  young  mice29.  However  in  older  mice  
with  pre-­‐exisiting  tau  pathology,  EpoD  reduces  hyper-­‐phosphorylated  tau40.    Consistent  with  
this,  intranasal  administration  of  NAP  for  3  months  reduces  tau  phosphorylated  at  AT8  and  
AT180  sites  in  triple  transgenic  AD  mice21.  In  contrast  to  these  findings,  we  did  not  observe  
any  significant  changes  in  levels  of  either  total  tau  or  in  phosphorylation  of  tau  at  the  sites  
we   examined   following   NAP   treatment.   This   suggests   that   NAP   is   not   affecting   tau  
degradation  or  phosphorylation  pathways.  It  is  possible  that  in  our  model,  where  very  early  
pre-­‐tangle   stages   of   disease   are   modelled   and   neuronal   dysfunction   prior   to   death   is  
assessed,   NAP-­‐mediated   protection   occurs   primarily   due   to   microtubule   stabilisation.  
However,  it  is  conceivable  that  after  prolonged  periods  of  NAP  treatment,  as  is  the  case  in  
studies  described  above21,  29,  40,  the  restoration  of  microtubule   integrity  reinstates  some  of  
the  homeostatic  mechanisms  (including  some  which  impact  tau-­‐phosphorylation)  that  may  
be   lost   in   the  presence  of  hyper-­‐phosphorylated   tau.     Our   finding   that  NAP   increases   the  




percentage  of  dtau  bound  to  MTs  which,  we  previously  showed  is  compromised  by  hyper-­‐
phosphorylated   htau4,   supports   this   argument.      We   speculate   that   this   occurs   because  
stabilization  of  MTs  by  NAP   increases  the  MT  surface  area  available  for  dtau  binding,   thus  
further   improving   MT   integrity.      As   the   level   of   dtau   and   the   pathological   dtau/htau  
interaction  is  unaltered  (this  is  not  surprising  given  that  this  interaction  is  dependent  upon  
the  phosphorylation  state  of  htau4,  which  is  unchanged  by  NAP),   it   is   likely  that  dtau  from  
the  soluble  cytosolic  pool  is  recruited  back  to  the  MTs.    Indeed  dtau  levels  were  reciprocally  
reduced  in  the  supernatant  fraction  of  NAP-­‐treated  animals.  
  
NAP  rescues  as  well  as  prevents  tau-­‐mediated  dysfunction  
An  important  consideration  for  therapies  aiming  to  target  dysfunctional  cellular  processes  is  
the   extent   of   damage   that   will   have   already   occurred   by   the   time   clinical   symptoms  
manifest.  We  therefore  ????????????????????????????????????????????????? ???????????????? ???
had  already  become  compromised  and  found  that  treatment  after  onset  of  dysfunction  was  
just  as  efficacious  as  prophylactic  treatment  before  onset.    This  is  supported  by  the  findings  
of  others  that  NAP  is  protective  when  administered  immediately  after  injury18,  41,  42  and  also  
when   given   chronically   after   the   onset   of   dysfunction   in   rodent   models   of   AD20,   22,   43.  
However,  these  studies  have  not   investigated  the  effect  of  NAP-­‐treatment  on  MT  integrity  
and  function.    Ours  is  the  first  study  to  investigate  ????????????????  both  MT  integrity  (EM)  
and  function  (axonal  transport)  after  the  onset  of  dysfunction  in-­‐vivo.  
  
Furthermore   NAP-­‐mediated   neuroprotection   was   long-­‐lasting,   both   in   our   model   and   in  
other  models  of  neuronal  injury18,44.  These  results  and  ours  are  intriguing  and  suggest  that,  
as  speculated  by  Sudo  and  Bass  (2011)38,  NAP  may  stabilise  the  microtubule  lattice  in  such  a  








The   mechanism(s)   by   which   abnormally   hyper-­‐phosphorylated   and   aggregated   tau   cause  
neuronal  dysfunction  and  neurodegeneration  in  tauopathies  like  ?????? ????????????   is  not  
entirely  clear.  The  general  consensus  is  that  disease-­‐associated  aberrations  (such  as  hyper-­‐
phosphorylation   in   AD   and  mutation   in   familial   tauopathies)  which   reduce   tau   binding   to  
microtubules   cause   cytoskeletal   destabilisation   leading   to   disruption   of   axonal   transport  
prior  to  tau  aggregation.  Thus  microtubule  stabilisation  and  restoration  of  axonal  transport  
is  probably   the  most  promising  disease-­‐modifying   therapeutic   target   to   counter  abnormal  
tau-­‐mediated  neuronal  dysfunction.  Our  results  support  this  view  by  demonstrating  that   a  
microtubule-­‐stabilising   drug   can   effectively   protect   against   all   hyper-­‐phosphorylated   tau-­‐
mediated   phenotypes   spanning   from   cellular   and   molecular   dysfunction   to   behavioural  
defects   in-­‐vivo.  Microtubule   stabilising  drugs   such  as  NAP   that  penetrate   the  BBB  and  are  
non-­‐toxic  therefore  hold  great  promise  for  the  treatment  of  all  tauopathies.  Encouragingly  
phase   II   clinical   trials   showed   promising   results   with   improvements   in   cognitive   scores,  
evidence  of  BBB  permeability  and  good  tolerability  in  patients  with  amnestic  mild  cognitive  
impairment45.   Therefore,   NAP   has   been   investigated   in   phase   II/III   clinical   trials   for   the  
??????????????????????????????????????????????????????severe  tauopathy45  and  the  results  of  
this  are  currently  being  evaluated.  Understanding  the  mode  of  action  of  NAP  will  pave  the  
way  for  similar  disease-­‐???????????????????? ????????? ????????????????????????????????hies  
that  have  thus  far  been  untreatable.    
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Figure  1.  NAP  improves  the  locomotor  phenotype  in  htau0N3R-­‐expressing  Drosophila.  Oral  
administration   of   2.5µg/ml   NAP   improves   the   locomotor   performance   of   htau0N3R  
wandering   third   instar   larvae.   (A-­‐C)   Traces   of   paths   taken   by   L3   larvae   in   2  minutes   free  
crawling  on  100cm2  plates   are   shown   for  OreR  controls   (A),  htau0N3R  untreated   larvae   (B)  
and   htau0N3R   larvae   treated   with   NAP   (C).   Crawling   performance   was   quantified   using   a  
tracking-­‐software  Ethovision.  2.5µg/ml  NAP  improved  crawling  performance  on  3  different  
measures:  body  wall  contractions  per  minute  (D),  velocity  (E)  and  meander  (F).     Scale  bar:  
2cm.      Error   bars   represent   mean   ±   S.E.M.,   (D-­‐F);   1-­‐way   ANOVA,   post-­‐???? ?????????????
Multiple  Comparison  Test,  P***<0.001  (body  wall  contractions);  P****<0.0001  (velocity);  P  
=  0.06  (meander).  n  =  16-­‐20).  
  
Figure   2.   NAP   protects   against   microtubule   destabilisation   in   htau0N3R   Drosophila.    
Representative  electron  micrographs  showing  transverse  sections  of  peripheral  nerves  in  L3  
larvae.   Axon   profiles   in   control   larvae   show   regularly   spaced   correctly-­‐aligned   transverse  
microtubules   (black   arrows   in   A-­‐C).   In   axons   of   htau0N3R      larvae   the   microtubules   were  
disrupted,  with   fewer   correctly   aligned   transverse  microtubules   (black   arrows   in  D-­‐F)   and  
more  disorganised  microtubules  visible  in  the  same  axon  profiles  (black  arrowheads  in  D-­‐F).  
Axons   relatively   devoid   of   microtubules   were   also   observed   (asterisks   in   F).   However,   in  
htau0N3R  larvae  fed  2.5µg/ml  NAP,  there  was  a  complete  rescue  of  microtubule  integrity  (G-­‐I).  
Scale   bar   500   nm.   Control   axons   contained   on   average   8.10   ±   0.20   correctly-­‐aligned  
microtubule  profiles  per  cross-­‐section;  larvae  expressing  htau0N3R  contained  only  5.32  ±  0.28,  
and  those  expressing  htau0N3R  but  reared  on  NAP  contained  8.07  ±  0.30  profiles  (J).  Average  
numbers   of   correctly-­‐aligned   visible  microtubule   profiles   in   axons   of   control   and   htau0N3R  
NAP   treated   animals  were   significantly   greater   than   those   of   untreated   htau0N3R   animals.    
Axons  exhibited  a  range  of  intact  correctly  aligned  transverse  microtubules  (K):  the  majority  
of   control   axons   contained   large   numbers   of   microtubules   (>5),   and   very   few   axons  
contained  no  microtubules.  However,  the  majority  of  htau0N3R  axons  contain  either  none  or  
very  few  microtubules  (<5).  Htau0N3R   larvae  reared  on  NAP  had  a  greater  number  of  axons  
containing   large  numbers  of   intact   transverse  microtubules   (>5)   and   fewer   axons  with  no  
microtubules   (k).   (Error   bars   represent   mean   ±   S.E.M.,   P**   <   0.01,   as   determined   by  
unpaired  Student?s  two-­‐tailed  t  test,  n=5).  
  
Figure  3.  NAP  prevents  axonal  transport  deficits  and   improves  NMJ  morphology.  Control  
NAP-­‐treated   and   untreated   larvae   showed   a   homogeneous   distribution   of   vGFP  
fluorescence   in  peripheral  nerves   (A.i,  B.i).  Htau0N3R   larvae   showed  accumulation  of   vGFP,  
indicative  of  disrupted  axonal  transport  (C.i).  2.5µg/ml  NAP  prevented  accumulation  of  vGFP  
in   htau0N3R   larvae   (D.i).   Larvae   were   reared   at   23°C.   Scale   bars:10µm.   The   total   area  




encompassed   by   vGFP   accumulates   was   greater   in   htau0N3R   larvae   compared   to   control.  
2.5µg/ml  (low)  and  25µg/ml  (high)  NAP  reduced  the  area  covered  by  vesicular  accumulates  
back   to  control   levels   (E).  Disruption  of  axonal  transport  was  also  evident   in  A?42;htau1N4R  
and  htau1N4R  expressing   larvae  when   reared  at  29°C.     NAP  treatment   significantly   reduced  
the  area  covered  by  vGFP  accumulates  in  both  lines  (F).  NMJs  on  muscle  4  were  revealed  by  
anti-­‐HRP  staining  (green)  and  the  tubulin  cytoskeleton  by  anti-­‐tubulin  staining  (red)  (Aii-­‐iv,  
Bii-­‐iv,  and  Cii-­‐iv).  Control  NAP-­‐treated  and  untreated  larvae  exhibited  a  characteristic  bead-­‐
like   distribution   of   presynaptic   boutons   (A.ii,   B.ii)   and   the   tubulin   cytoskeleton   extended  
into   the   distal   ends   of   the  NMJ   (A.iii,   B.iii).  Morphological   aberrations   (thinning   of   inter-­‐
????????????????????????? ?????????????????????????????????????????0N3R  ?????  (arrowheads  
in  C.ii).  Anti-­‐tubulin  staining  showed  disruption  of  the  cytoskeleton,  with  complete  absence  
in   the  most  distal   regions  of   the  NMJ   (asterisk   in  C.iii).   The  NMJs  of  htau0N3R  NAP-­‐treated  
animals  contained  a  greater  number  of  satellite  boutons  (arrowheads   in  D.ii)  compared  to  
untreated  animals.  However,   restoration  and  extension  of   the   cytoskeleton   into   the  most  
distal  ends  of  the  NMJ  was  observed  (asterisk   in  D.iii).  Anti-­‐HRP  and  tubulin  overlay  (A.iv-­‐
D.iv).  Quantification  of   the  area  encompassed  ????????   shows  a  significantly  smaller  NMJ  
area  in  htau0N3R-­‐expressing  larvae  when  compared  to  controls.    NAP  treatment  significantly  
increases  the  NMJ  area  in  htau0N3R-­‐expressing  larvae  (G).  Error  bars  represent  mean  ±  S.E.M.,  
(E,   G;   ANOVA,   post-­‐hoc   Bonf????????? ????????? ??????????? ????,   P*<0.05;   P***<0.001;  
P****<0.0001),   (F????????????????????? ???-­‐tailed   t   test,  P*<0.05;  P**<0.01).  n=10   (E),  n=5  
(F),  n=3-­‐5  (G).    
  
Figure   4.   NAP   does   not   alter   tau   phosphorylation   at   a   number   of   sites   relevant   to   AD,  
however   it   increases   dtau   binding   to   the   microtubules   without   altering   the   dtau/htau  
interaction.  For  each  phospho-­‐tau  antigen,  intensity  of  signal  (pixels/mm2)  was  normalised  
to   total   tau.   There   was   no   significant   change   in   the   levels   of   the   phospho-­‐tau   epitopes  
detected  by  AT8   (A),  AT180   (B),  PS262   (C)   and  PHF-­‐1   (D)   after   treatment  with  NAP.   Total  
dtau   and   htau   levels   were   not   altered   by   NAP   treatment   (E,   F).   Representative   blots   are  
shown   below   relevant   graphs   (A-­‐F).      Microtubule-­‐binding   assays   were   performed   using    
larvae  (G,  I)  or  1-­‐3day  old  adult  fly  heads  (H,  J)  expressing  htau0N3R  treated  with  or  without  
2.5µg/ml     NAP.     Brain  extracts  were   fractionated  to  yield  a  microtubule  pellet   (MT)  and  a  
soluble   supernatant   (SN).   Both   fractions   were   probed   with   anti-­‐htau   and   anti-­‐dtau  
antibodies.  Treatment  with  NAP  increased  binding  of  endogenous  dtau  to  the  microtubules  
(G,  H)  but  did  not  alter  binding  of  htau  to  mictrotubules  (I,   J).  Soluble  human  tau  binds  to  
Drosophila  tau  in  a  phosphorylation-­‐dependent  manner.  An  anti-­‐htau  antibody  was  used  to  
precipitate  out  htau   from  1-­‐3-­‐day-­‐old   adult   fly  heads  expressing  htau0N3R,   treated  with  or  
without  2.5µg/ml  NAP.  Dtau  co-­‐immunoprecipitated  with  htau  and  NAP-­‐treatment  did  not  
alter   this   interaction   (K).   All   lanes   were   run   on   the   same   gel;   however   (E)   was   non-­‐
contiguous.  (Error  bars  represent  mean  ±  S.E.M.,  P????????????????????????????????-­‐tailed  t  
test,  n=5-­‐7    (E-­‐F),  n=  3-­‐5  (G-­‐K)).  
  
Figure  5.  24  hour  NAP  treatment  rescues  the  tau-­‐mediated  axonal  transport  phenotype.    
The   total   area   encompassed   by   vGFP   accumulates  was   quantified   over   a   pre-­‐determined  
region   of   peripheral   nerves   in   L3   larvae.   A   disruption   of   axonal   transport   was   evident   in  
untreated   htau0N3R   larvae   at   day   4   (early   L3)   (light   grey   bar,   far   left)   and   became  
progressively  worse  by  day  5  (black  bar).  However  NAP  treatment  for  24  hours  (white  bar)  
significantly   reduced   the  area   covered  by   vesicular   accumulates   to   the   same   level   as   that  




seen  in  larvae  treated  with  NAP  for  5  days  (striped  bar),  thus  rescuing  the  axonal  transport  
deficit  once  established.  NAP  treatment  for  4  days  followed  by  transfer  of  larvae  to  normal  
food   for   24  hours  was   also   sufficient   to  maintain   protection   at   day   5   (dark   grey   bar)   (A).  
Representative   vGFP-­‐tagged   vesicle   distribution   in   htau0N3R,   L3   larval   peripheral   nerves  
treated  for  24  hours  with  2.5µg/ml  NAP  (B).  Scale  bar:  10µm.  (Error  bars  represent  mean  ±  
S.E.M.,  P**  <  0.01;  P****  <  0.0001,  ANOVA,  post-­‐hoc  Bo??????????? ?????????????????????????
n=10).  
  






















Supplementary   Figure   1.   NAP   does   not   affect   crawling   behaviour   of   controls.      Crawling  
performance  of  OreR  controls  was  quantified  using  a  tracking-­‐software  Ethovision.  2.5µg/ml  
NAP  did  not  alter  the  crawling  performance  as  assessed  by  3  different  measures:  body  wall  
contractions   per  minute   (A),   velocity   (B)   and  meander   (C).   (Error   bars   represent  mean   ±  
S.E.M.,  P  ??????????????????????????????-­‐tailed  t  test,  n  =  16-­‐24).  
  
Supplementary   Video   1   Video   showing   locomotion   of   htau0N3R   larvae.   4   representative  
larvae  are  shown  in  separate  arenas.  
  
Supplementary  Video  2  Video  showing  locomotion  of  OreR  larvae.  4  representative  larvae  
are  shown  in  separate  arenas.  
  
Supplementary   Video   3   Video   showing   locomotion   of   htau0N3R   larvae   fed   NAP.   4  
representative  larvae  are  shown  in  separate  arenas.  
  
Supplementary  Figure  2.  NAP  does  not  increase  microtubule  numbers  in  controls.  
Representative  electron  micrographs  showing  transverse  sections  of  peripheral  nerves  in  L3  
larvae.  Axon  profiles   in  both  untreated   (A,   B)   and  NAP-­‐treated   (C,  D)   control   larvae   show  
regularly  spaced  correctly-­‐aligned  transverse  microtubules.  Scale  bar  200  nm.  Control  axons  
contained  on  average  9.22  ±  0.42   correctly-­‐aligned  microtubule  profiles  per   cross-­‐section,  
whilst  control  larvae  reared  on  NAP  contained  9.98  ±  0.45  such  profiles,  P  =  0.22  (E).  (Error  
bars  represent  mean  ±  S.E.M.,  P    ??????????????????????????????-­‐tailed  t  test,  n=3.  
  
Supplementary   Figure  3.  H-­‐tau   levels   are   comparable  between   tau-­‐isoforms.     There  was  
no   significant   difference   in   the   levels   of   total   h-­‐tau   between   htau1N4R?? ??42;htau1N4R   and  
htau0N3R  isoforms.    Larvae  were  reared  at  23°C.  (Error  bars  represent  mean  ±  S.E.M.,  P  <  0.05,  
unpaired  Students  two-­‐tailed  t  test,  n=4).  





Supplementary   Figure   4.   NAP   does   not   alter   tau   phosphorylation   at   a   number   of   sites  
relevant  to  AD  in  1-­‐3  day-­‐old  adult  flies.  For  each  phospho-­‐tau  antigen,  intensity  of  signal  
(pixels/mm2)  was  normalised   to  total   tau.   There  was  no  significant  change   in  the   levels  of  
the  phospho-­‐tau  epitopes  detected  by  AT8   (A),  AT180   (B),   PS262   (C)   PHF-­‐1   (D)   and   tau-­‐1  
(dephosphorylated  tau  at  Ser199/  Ser  202/  Thr  205)  (E)  after  treatment  with  NAP.  Htau  and  
dtau   levels  were  not  altered  by  NAP  treatment  (F,  G).  All   lanes  were  run  on  the  same  gel,  
and  were   contiguous.   Representative   blots   are   shown  below   relevant   graphs   (A-­‐G)   (Error  
bars  represent  mean  ±  S.E.M.,  P  <  0.05,  unpaired  Students  two-­‐tailed  t  test,  n=7).  
  
Supplementary  Figure  5.  NAP  treatment  is  not  toxic  for  Drosophila  larvae  or  adults.  There  
was  no  significant  difference  in  the  rate  of  pupation  (A)  or  ecclosion  (B)  of  control  untreated  
and   NAP   treated   animals.   The   ecclosion   rate   of   htau0N3R   pupae  was   also   not   significantly  
altered  by  treatment  with  NAP  (C).  (Error  bars  represent  mean  ±  S.E.M.,  P  <  0.05,  unpaired  
Students  two-­‐tailed  t  test,  n=4-­‐8).  Methods  for  Supplementary  Figure  5.  Toxicity  assay:  All  
treatment  groups  were  subjected  to  a  3-­‐4  hour  timed  lay  on  apple  juice  agar  plates.  F1  eggs  
were  transferred  to  either  basic  food  or  NAP  food.  The  number  of  larvae  that  pupated  and  
ecclosed  was  scored  as  a  percentage  of  eggs  laid.    
 
















Quraishe et al., 2012 
 
34 
 
  
